[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338635-105":59,"doc-detail-338635-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-cd200-in-breast-cancer-opportunities-and-challenges-in-immunotherapeutic-strategies","Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies","","Tumor progression and therapeutic resistance often originate from an immunosuppressive tumor microenvironment. CD200, a cell-surface glycoprotein, is described as a key breast cancer molecule that modulates immune responses through its receptor CD200R. The CD200–CD200R interaction suppresses antitumor immune activity, enabling immune evasion and escape. This review summarizes advances and future directions for CD200-targeted cancer therapies and highlights molecular pathways with variable expression across cancer types to inform treatment options.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-cd200-in-breast-cancer-opportunities-and-challenges-in-immunotherapeutic-strategies/338635/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-cd200-in-breast-cancer-opportunities-and-challenges-in-immunotherapeutic-strategies/338635.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does the CD200–CD200R interaction influence breast cancer progression?","Question",{"text":112,"@type":113},"CD200 binds CD200R and suppresses immune activities against tumor cells. This allows tumor cells to be less detectable to immune cells, supporting immune escape and tumor development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is CD200 considered a promising therapeutic target in breast cancer?",{"text":117,"@type":113},"Therapies that target CD200 and/or block the CD200/CD200R interaction are proposed to improve antitumor immune responses. The review also notes that expression differences across subtypes may complicate management but provide targeting opportunities.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors affect patient response to CD200-targeted therapy?",{"text":121,"@type":113},"Variability arises from differences in the tumor microenvironment and from genetic and epigenetic variations affecting CD200 targeting. CD200 and CD200R expression patterns also differ across cancer types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338635,1790500476,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?_k=1776742907772140068","Review  \nTargeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies  \nSihyang Baek 1 and Kui Cui 2, *  \nAcademic Editor: Kuo-Hu Chen  \nReceived: 24 September 2024  \nRevised: 16 December 2024  \nAccepted: 23 December 2024  \nPublished: 26 December 2024  \nCitation: Baek, S.; Cui, K. Targeting  \nCD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies. Int. J. Mol. Sci. 2025, 26, 115 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26010115  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Western Reserve Academy, Hudson, OH 44236, USA; [christinesbaek@gmail.com](christinesbaek@gmail.com)  \n2 Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA  \n* Correspondence: [kui.cui@childrens.harvard.edu](kui.cui@childrens.harvard.edu); Tel.: +1-617-919-2435  \nAbstract: One of the key factors that contribute to tumor progression and resistance is the immunosuppressive microenvironment of the tumor. CD200 is a recently identified cell surface glycoprotein recognized as an important molecule in breast cancer for its versatile modulation of the immune response via its receptor, CD200R. The interaction between CD200 and CD200R suppresses the immune activities against tumor cells and allows them to be undetected and, in doing so, to escape from the destructive capability of the immune cells. Here, we review recent advances and future trends in CD200-targeted therapies for cancer treatments. We also discuss molecular pathways that include variable expressions across different cancer types and their importance in treatment options.  \nKeywords: CD200; CD200R; breast cancer; immune evasion  \n1. Introduction  \nBreast cancer is one of the most prevalent cancers and a leading cause of death among women. The search for new therapeutic targets and treatment strategies is urgently needed. Central to this interest is CD200, a cell surface glycoprotein involved in the negative regulation of immune responses [1,2] . CD200 binds to its cognitive receptor, CD200R, and the CD200/CD200R interactions regulate the immune tolerance and weaken antitumor immunity within the tumor microenvironment [3] . CD200 expressed in the tumor cell surface interacts with CD200R present in the membrane of various immune cells, and this molecular interaction provides an immune status capable of allowing tumor development and metastasis, while protecting the cancer cells from immune damage [4,5] . CD200 is expressed by many cell types, including tumor cells. Studies show that CD200 inhibits myeloid immune cell activities [6,7] . Specifically, CD200 has been associated with pathologic and prognostic outcomes in breast cancers [8] . For example, its expression differs significantly among breast cancer subtypes and influences its tumor behavior and treatment responses. This expression variation in different subtypes is a chief complication in clinical management, but a good potential therapeutic target [6,9] . Initial clinical trials are found tobe promising based on the cumulative experimental and clinical evidence pointing to the potential of therapies targeting CD200 to enhance current chemotherapy and/or immunotherapy strategies [10] . However, we need a good understanding of the tumor microenvironment and its regulation mechanisms, considering the complex repertoire of molecular interactions between the tumor and the immune system of the microenvironment, as well as the opposing roles of CD200 in both tumor growth suppression and promotion [1] . Moreover, genetic and epigenetic variations in the therapeutic targeting of CD200","cbCaibalYlRrSmQR","https://ap.wps.com/l/cbCaibalYlRrSmQR","pdf",558769,"English","# Abstract\n# 1. Introduction\n# 2. CD200 Introduction to Cancer Biology","[{\"question\":\"How does the CD200–CD200R interaction influence breast cancer progression?\",\"answer\":\"CD200 binds CD200R and suppresses immune activities against tumor cells. This allows tumor cells to be less detectable to immune cells, supporting immune escape and tumor development.\"},{\"question\":\"Why is CD200 considered a promising therapeutic target in breast cancer?\",\"answer\":\"Therapies that target CD200 and/or block the CD200/CD200R interaction are proposed to improve antitumor immune responses. The review also notes that expression differences across subtypes may complicate management but provide targeting opportunities.\"},{\"question\":\"What factors affect patient response to CD200-targeted therapy?\",\"answer\":\"Variability arises from differences in the tumor microenvironment and from genetic and epigenetic variations affecting CD200 targeting. CD200 and CD200R expression patterns also differ across cancer types.\"}]","Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies | PDF",1790024705,48]